Ka-Won Kang1, Jik-Han Jung2, Woojune Hur1, Jaena Park3, Hyunku Shin3, Byeonghyeon Choi4, Hyesun Jeong5, Dae Sik Kim1, Eun Sang Yu1, Se Ryeon Lee1, Hwa Jung Sung1, Seok Jin Kim6, Chul Won Choi1, Hyun Koo Kim4, Sunghoi Hong5, Ji-Ho Park2, Yeonho Choi3, Yong Park7, Byung Soo Kim1. 1. Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. 2. Department of Bio and Brain Bioengineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. 3. Department of Bio-convergence Engineering, Korea University, Seoul, Republic of Korea. 4. Department of Thoracic and Cardiovascular Surgery, Korea University College of Medicine, Seoul, Republic of Korea. 5. School of Biosystem and Biomedical Science, Korea University, Seoul, Republic of Korea. 6. Division of Hematology-Oncology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 7. Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea paark76@hanmail.net.
Abstract
BACKGROUND/AIM: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. MATERIALS AND METHODS: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. RESULTS: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. CONCLUSION: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript. Copyright
BACKGROUND/AIM: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. MATERIALS AND METHODS:Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. RESULTS: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the humanBCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. CONCLUSION: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript. Copyright
Authors: Mohieddin Barzegar; Mehdi Allahbakhshian Farsani; Mohammad Rafiee; Vahid Amiri; Sayeh Parkhihdeh; Fariba Rad; Mohammad Hossein Mohammadi Journal: Ann Hematol Date: 2021-07-08 Impact factor: 3.673
Authors: Giuseppe Lia; Clara Di Vito; Marco Cerrano; Lucia Brunello; Francesca Calcaterra; Marta Tapparo; Luisa Giaccone; Domenico Mavilio; Benedetto Bruno Journal: Front Immunol Date: 2020-03-20 Impact factor: 7.561